Ocuphire Pharma, Inc. announced that it has entered into common stock purchase agreement with new investor Lincoln Park Capital Fund, LLC, a fund managed by Lincoln Park Capital, LLC to issue common shares for the gross proceeds of $50,000,000 on August 10, 2023. Upon the execution of the Purchase Agreement, the Company issued 246,792 shares of common stock to Lincoln Park and paid Lincoln Park $40,000, which together represents the fee for Lincoln Park?s commitment to purchase shares of the Company?s common stock under the Purchase Agreement. The investor can purchase up to $50,000,000 common shares over a 30-month period at prices per share as computed under the Purchase Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.73 USD | +1.76% | -5.46% | -42.52% |
May. 10 | Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.52% | 43.53M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Ocuphire Pharma, Inc. announced that it expects to receive $50 million in funding from Lincoln Park Capital, LLC